Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines

Wilson,Claire  H.; Abbott,Catherine  A.

doi:10.3892/ijo.2012.1522

Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines

Authors:
- Claire H. Wilson
- Catherine A. Abbott
View Affiliations

Affiliations: School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
Published online on: June 19, 2012 https://doi.org/10.3892/ijo.2012.1522
Pages: 919-932

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Proteases, particularly serine proteases like dipeptidyl peptidase 4 (DP4) and fibroblast activation protein (FAP), play an important role in cancer invasion and angiogenesis. Aberrant expression of DP4 and FAP is associated with numerous cancers, including breast and epithelial ovarian carcinoma. We investigated the mRNA levels, protein expression and enzyme activity of the structural homologs DP8 and DP9, in addition to DP4 and FAP, in three breast carcinoma (MDA-MB-231, MDA-MB-453, MCF-7), three epithelial ovarian carcinoma (EOC) (OVCA-432, OVCA-429, SKOV3), 293T and HeLa cell lines. In addition, DP2 and prolyl endopeptidase (PEP) mRNA and enzyme levels were measured and compared in each cell line. Ubiquitous but differential expression of DP8 and DP9 mRNA and protein was observed across all cell lines. Relative to EOC, DP8 protein was lower in the breast carcinoma cell lines (p=0.057), suggesting that DP8 may play differing roles in different cancer cell types. A strong, negative, non-reciprocal relationship was identified between DP9 protein and DP4 mRNA (r=-0.903, p=0.002) and protein (r=-0.810, p=0.015). This suggests that DP4 expression plays an important role in the post-transcriptional regulation of DP9 in breast and ovarian cancer cell lines. Overall, this study suggests a potential role for DP8 and DP9 in breast and ovarian cancer and further investigations in this area are required.

View Figures

View References

1.	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Cho KR and Shih Ie M: Ovarian cancer. Annu Rev Pathol. 4:287–313. 2009. View Article : Google Scholar
3.	Schnitt SJ: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 23(Suppl 2): S60–S64. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Kurman RJ and Shih Ie M: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 27:151–160. 2008.PubMed/NCBI
5.	Lambeir AM, Durinx C, Scharpe S and De Meester I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 40:209–294. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Bjelke JR, Christensen J, Nielsen PF, Branner S, Kanstrup AB, Wagtmann N and Rasmussen HB: Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J. 396:391–399. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Ajami K, Pitman MR, Wilson CH, Park J, Menz RI, Starr AE, Cox JH, Abbott CA, Overall CM and Gorrell MD: Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett. 582:819–825. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Keane FM, Nadvi NA, Yao TW and Gorrell MD: Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J. 278:1316–1332. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Busso N, Wagtmann N, Herling C, Chobaz-Peclat V, Bischof-Delaloye A, So A and Grouzmann E: Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol. 166:433–442. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Barbieri F, Bajetto A and Florio T: Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol. 2010:4269562010. View Article : Google Scholar : PubMed/NCBI
11.	Ali S and Lazennec G: Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev. 26:401–420. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Balkwill F: Cancer and the chemokine network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar
13.	Mentlein R: Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept. 85:9–24. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Sun YX, Pedersen EA, Shiozawa Y, Havens AM, Jung Y, Wang J, Pienta KJ and Taichman RS: CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis. 25:765–776. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Arscott WT, La Bauve AE, May V and Wesley UV: Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene. 28:479–491. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, Jeha D, Hanafy J, Lee CK, Sun J, Izycka-Swiezczewska E, Toretsky JA and Kitlinska J: Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors. J Biol Chem. 286:27494–27505. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Yu DM, Wang XM, McCaughan GW and Gorrell MD: Extra-enzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J. 273:2447–2460. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Wang XM, Yu DM, McCaughan GW and Gorrell MD: Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 42:935–945. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Sulda ML, Abbott CA and Hildebrandt M: DPIV/CD26 and FAP in cancer: a tale of contradictions. Adv Exp Med Biol. 575:197–206. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Johnson RC, Zhu D, Augustin-Voss HG and Pauli BU: Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells. J Cell Biol. 121:1423–1432. 1993. View Article : Google Scholar : PubMed/NCBI
21.	Cheng HC, Abdel-Ghany M, Elble RC and Pauli BU: Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem. 273:24207–24215. 1998. View Article : Google Scholar : PubMed/NCBI
22.	Cheng HC, Abdel-Ghany M, Zhang S and Pauli BU: Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer? Clin Exp Metastasis. 17:609–615. 1999. View Article : Google Scholar : PubMed/NCBI
23.	Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K and Mizutani S: Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res. 62:2753–2757. 2002.PubMed/NCBI
24.	Kajiyama H, Shibata K, Ino K, Mizutani S, Nawa A and Kikkawa F: The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells. Cancer Sci. 101:347–354. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Garin-Chesa P, Old LJ and Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 87:7235–7239. 1990. View Article : Google Scholar
26.	Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N, Yamane T, Mori Y, Mitsumata M, Ghersi G and Chen WT: Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res. 66:9977–9985. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT: Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 330:827–830. 2010. View Article : Google Scholar : PubMed/NCBI
28.	Kelly T, Kechelava S, Rozypal TL, West KW and Korourian S: Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Mod Pathol. 11:855–863. 1998.PubMed/NCBI
29.	Ariga N, Sato E, Ohuchi N, Nagura H and Ohtani H: Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer. 95:67–72. 2001. View Article : Google Scholar
30.	Goodman JD, Rozypal TL and Kelly T: Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis. 20:459–470. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Huang Y, Wang S and Kelly T: Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. 64:2712–2716. 2004. View Article : Google Scholar : PubMed/NCBI
32.	Kennedy A, Dong H, Chen D and Chen WT: Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer. 124:27–35. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW and Gorrell MD: Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 267:6140–6150. 2000. View Article : Google Scholar : PubMed/NCBI
34.	Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW and Gorrell MD: The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J. 277:1126–1144. 2010. View Article : Google Scholar : PubMed/NCBI
35.	Dubois V, Van Ginneken C, De Cock H, Lambeir AM, Van der Veken P, Augustyns K, Chen X, Scharpe S and De Meester I: Enzyme activity and immunohistochemical localization of dipeptidyl Peptidase 8 and 9 in male reproductive tissues. J Histochem Cytochem. 57:531–541. 2009. View Article : Google Scholar : PubMed/NCBI
36.	Yao TW, Kim WS, Yu DM, Sharbeen G, McCaughan GW, Choi KY, Xia P and Gorrell MD: A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res. 9:948–959. 2011. View Article : Google Scholar : PubMed/NCBI
37.	Sulda ML, Abbott CA, Macardle PJ, Hall RK and Kuss BJ: Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia. Cancer Biol Ther. 10:180–189. 2010. View Article : Google Scholar : PubMed/NCBI
38.	Yu DM, Ajami K, Gall MG, Park J, Lee CS, Evans KA, McLaughlin EA, Pitman MR, Abbott CA, McCaughan GW and Gorrell MD: The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem. 57:1025–1040. 2009. View Article : Google Scholar : PubMed/NCBI
39.	Stremenova J, Mares V, Lisa V, Hilser M, Krepela E, Vanickova Z, Syrucek M, Soula O and Sedo A: Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas. Int J Oncol. 36:351–358. 2010.PubMed/NCBI
40.	Stremenova J, Krepela E, Mares V, Trim J, Dbaly V, Marek J, Vanickova Z, Lisa V, Yea C and Sedo A: Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int J Oncol. 31:785–792. 2007.PubMed/NCBI
41.	Soule HD, Vazguez J, Long A, Albert S and Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 51:1409–1416. 1973.PubMed/NCBI
42.	Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP and Johnson PH: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 61:5168–5178. 2001.PubMed/NCBI
43.	Crow MJ, Grant G, Provenzale JM and Wax A: Molecular imaging and quantitative measurement of epidermal growth factor receptor expression in live cancer cells using immunolabeled gold nanoparticles. AJR Am J Roentgenol. 192:1021–1028. 2009. View Article : Google Scholar : PubMed/NCBI
44.	Lau KM, Mok SC and Ho SM: Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA. 96:5722–5727. 1999. View Article : Google Scholar : PubMed/NCBI
45.	Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB and Koeffler HP: 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 104:2701–2708. 2005. View Article : Google Scholar : PubMed/NCBI
46.	Xu F, Yu Y, Le XF, Boyer C, Mills GB and Bast RC: The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res. 5:3653–3660. 1999.PubMed/NCBI
47.	Hua W, Christianson T, Rougeot C, Rochefort H and Clinton GM: SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol. 55:279–289. 1995. View Article : Google Scholar : PubMed/NCBI
48.	Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M and Deisseroth AB: Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst. 89:1271–1276. 1997. View Article : Google Scholar : PubMed/NCBI
49.	Monje P and Boland R: Expression and cellular localization of naturally occurring beta estrogen receptors in uterine and mammary cell lines. J Cell Biochem. 86:136–144. 2002. View Article : Google Scholar : PubMed/NCBI
50.	Lossos IS, Czerwinski DK, Wechser MA and Levy R: Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia. 17:789–795. 2003. View Article : Google Scholar : PubMed/NCBI
51.	Maes MB, Dubois V, Brandt I, Lambeir AM, Van der Veken P, Augustyns K, Cheng JD, Chen X, Scharpe S and De Meester I: Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukocyte Biol. 81:1252–1257. 2007. View Article : Google Scholar : PubMed/NCBI
52.	Abbott CA and Gorrell MD: The family of CD26/DPIV related ectopeptidases. Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology. Langner J and Ansorge S: Kluwer/Plenum; New York: pp. 171–195. 2002, View Article : Google Scholar
53.	Balaziova E, Busek P, Stremenova J, Sromova L, Krepela E, Lizcova L and Sedo A: Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-alpha in transformed astrocytic cells. Mol Cell Biochem. 354:283–289. 2011. View Article : Google Scholar : PubMed/NCBI
54.	Ajami K, Abbott CA, McCaughan GW and Gorrell MD: Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta. 1679:18–28. 2004. View Article : Google Scholar : PubMed/NCBI
55.	Pitman MR, Menz RI and Abbott CA: Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DP8). Biol Chem. 391:959–972. 2010. View Article : Google Scholar : PubMed/NCBI
56.	Bank U, Heimburg A, Wohlfarth A, Koch G, Nordhoff K, Julius H, Helmuth M, Breyer D, Reinhold D, Tager M and Ansorge S: Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects. Biol Chem. 392:169–187. 2011. View Article : Google Scholar : PubMed/NCBI
57.	Ansorge S, Nordhoff K, Bank U, Heimburg A, Julius H, Breyer D, Thielitz A, Reinhold D and Tager M: Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem. 392:153–168. 2011. View Article : Google Scholar : PubMed/NCBI
58.	Kikkawa F, Kajiyama H, Ino K, Shibata K and Mizutani S: Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. Int J Cancer. 105:779–783. 2003. View Article : Google Scholar : PubMed/NCBI
59.	Huang Y, Simms AE, Mazur A, Wang S, Leon NR, Jones B, Aziz N and Kelly T: Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis. 28:567–579. 2011. View Article : Google Scholar : PubMed/NCBI
60.	Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, Zhang Y, Kraus ML, Salakian S, Sridhar V, Wijnands R and Tennant MG: Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem. 280:19441–19444. 2005. View Article : Google Scholar : PubMed/NCBI
61.	Chiravuri M, Agarraberes F, Mathieu SL, Lee H and Huber BT: Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. J Immunol. 165:5695–5702. 2000. View Article : Google Scholar : PubMed/NCBI
62.	Tang HK, Tang HY, Hsu SC, Chu YR, Chien CH, Shu CH and Chen X: Biochemical properties and expression profile of human prolyl dipeptidase DPP9. Arch Biochem Biophys. 485:120–127. 2009. View Article : Google Scholar : PubMed/NCBI
63.	Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT and Thornberry NA: Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J. 371:525–532. 2003. View Article : Google Scholar : PubMed/NCBI
64.	Maes MB, Martinet W, Schrijvers DM, Van der Veken P, De Meyer GR, Augustyns K, Lambeir AM, Scharpe S and De Meester I: Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol. 72:70–79. 2006. View Article : Google Scholar : PubMed/NCBI
65.	Danilova O, Li B, Szardenings AK, Huber BT and Rosenblum JS: Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. Bioorg Med Chem Lett. 17:507–510. 2007.
66.	Hui M and Hui KS: A novel aminopeptidase with highest preference for lysine. Neurochem Res. 31:95–102. 2006. View Article : Google Scholar : PubMed/NCBI
67.	Claperon C, Banegas-Font I, Iturrioz X, Rozenfeld R, Maigret B and Llorens-Cortes C: Identification of threonine 348 as a residue involved in aminopeptidase A substrate specificity. J Biol Chem. 284:10618–10626. 2009. View Article : Google Scholar : PubMed/NCBI
68.	Fukasawa KM, Hirose J, Hata T and Ono Y: Aspartic acid 405 contributes to the substrate specificity of aminopeptidase B. Biochemistry. 45:11425–11431. 2006. View Article : Google Scholar : PubMed/NCBI
69.	Drag M, Bogyo M, Ellman JA and Salvesen GS: Aminopeptidase fingerprints, an integrated approach for identification of good substrates and optimal inhibitors. J Biol Chem. 285:3310–3318. 2010. View Article : Google Scholar : PubMed/NCBI
70.	Tenorio-Laranga J, Venalainen JI, Mannisto PT and Garcia-Horsman JA: Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J. 275:4415–4427. 2008. View Article : Google Scholar : PubMed/NCBI
71.	Edosada CY, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W and Wolf BB: Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 580:1581–1586. 2006. View Article : Google Scholar : PubMed/NCBI
72.	Cheng JQ, Lindsley CW, Cheng GZ, Yang H and Nicosia SV: The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 24:7482–7492. 2005. View Article : Google Scholar : PubMed/NCBI
73.	Hernandez-Aya LF and Gonzalez-Angulo AM: Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 16:404–414. 2011. View Article : Google Scholar : PubMed/NCBI
74.	Zagouri F, Dimopoulos MA, Bournakis E and Papadimitriou CA: Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. Eur J Gynaecol Oncol. 31:268–277. 2010.PubMed/NCBI
75.	Mazzoletti M and Broggini M: PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem. 17:4433–4447. 2010. View Article : Google Scholar : PubMed/NCBI
76.	Dickson RB, Thompson EW and Lippman ME: Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. J Steroid Biochem Mol Biol. 37:305–316. 1990. View Article : Google Scholar : PubMed/NCBI
77.	Kim HJ, Cui X, Hilsenbeck SG and Lee AV: Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 12:S1013–S1018. 2006. View Article : Google Scholar : PubMed/NCBI
78.	Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006. View Article : Google Scholar : PubMed/NCBI
79.	Oakman C, Viale G and Di Leo A: Management of triple negative breast cancer. Breast. 19:312–321. 2010. View Article : Google Scholar : PubMed/NCBI
80.	Rao BR, Slotman BJ, Geldof AA and Dinjens WN: Correlation between tumor histology, steroid receptor status, and adenosine deaminase complexing protein immunoreactivity in ovarian cancer. Int J Gynecol Pathol. 9:47–54. 1990. View Article : Google Scholar